We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Promethean | LSE:PTH | London | Ordinary Share | GB00B08H5G38 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 3.125 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
Hot Features
Premium
RNS Number:4672L
PPL Therapeutics PLC
22 May 2003
PPL Therapeutics plc ("the Company")
DISCLOSURE OF INTEREST
The Company received notification today from James Sharp & Co., that Mr David
Barry has an interest in 3,608,000 Ordinary shares in the Company, representing
3.04% of the Company's issued share capital. The shares are registered in the
name of Value Investments Limited.
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLUURBROVRVUAR
1 Year Promethean Chart |
1 Month Promethean Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
